Aprogen Biologics amends KRW 20 billion share sale to fund loan to Einspack
Bitget2026/09/23 06:23- Aprogen Biologics issued a correction to its Sept. 3 paid-in capital increase filing, reclassifying the funding purpose to “other funds.”
- The KRW 20 billion third-party allotment will fund strategic lending to EinsPack to support financial structure improvements.
- Shares to be issued remain 12,706,481 common shares at KRW 1,574 each, a 10% discount to a KRW 1,748 reference price.
- The allottee remains controlling shareholder Aprogen, subject to a one-year lock-up from the listing date.
- Payment date is Sept. 23, 2026; listing is scheduled for Oct. 13, 2026.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Honda Motor (HMC.US) Reports 65.7% Increase in Net Profit in the First Half, Plans to Expand Production Capacity in North America and Brazil
Honda Motor (HMC.US) released its financial results for the first half of fiscal year 2027 on November 10.
Crypto winter not over? Mining rig hosting provider Bitari cancels orders at the last minute, IPO plans put on hold
Bitcoin mining service provider Bitari has withdrawn its Nasdaq IPO plan. The company originally intended to issue 4.3 million shares at $7 per share to raise $30 million. Its annual revenue is approximately $11 million.
Pre-orders for GTA 6 are booming and may reverse the downward trend! Citigroup raises Take-Two Interactive Software (TTWO.US) target to $270
Citigroup maintains a "Buy" rating on Take-Two Interactive Software, with a target price of $270.
Silver Price Forecast: XAG/USD trades flat around $53 ahead of US inflation data
Crypto prices
More
